NCT03179917 - Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2017

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Hodgkin Lymphoma

Interventions

DRUG

Pembrolizumab

pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Pediatric patients will be treated at 2 mg/kg with a maximum dose of 200 mg.

RADIATION

Involved Site Radiation Therapy

30 Gy of ISRT

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

33136

University of Miami, Miami

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

19104-4283

Abramson Cancer Center at University of Pennsylvania (Data Collection Only), Philadelphia

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER